SCA
BSX icon

Snowden Capital Advisors’s Boston Scientific BSX Stock Holding History

Snowden Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588K Sell
13,777
-690
-5% -$37.5K 0.01% 775
2026
Q1 		$908K Sell
14,467
-3,790
-21% -$303K 0.02% 564
2025
Q4 		$1.74M Sell
18,257
-4,687
-20% -$460K 0.05% 368
2025
Q3 		$2.24M Buy
22,944
+2,551
+13% +$264K 0.06% 299
2025
Q2 		$2.19M Sell
20,393
-2,864
-12% -$290K 0.06% 286
2025
Q1 		$2.35M Buy
23,257
+1,860
+9% +$187K 0.08% 266
2024
Q4 		$1.91M Sell
21,397
-2,314
-10% -$204K 0.06% 313
2024
Q3 		$1.99M Sell
23,711
-486
-2% -$38.3K 0.06% 323
2024
Q2 		$1.86M Sell
24,197
-471
-2% -$34.5K 0.06% 331
2024
Q1 		$1.69M Buy
24,668
+3,247
+15% +$209K 0.05% 360
2023
Q4 		$1.24M Sell
21,421
-1,949
-8% -$104K 0.05% 388
2023
Q3 		$1.23M Sell
23,370
-578
-2% -$30.3K 0.05% 361
2023
Q2 		$1.3M Sell
23,948
-4,485
-16% -$234K 0.05% 391
2023
Q1 		$1.42M Buy
28,433
+3,392
+14% +$160K 0.06% 368
2022
Q4 		$1.16M Sell
25,041
-247
-1% -$10.7K 0.05% 418
2022
Q3 		$979K Buy
25,288
+207
+0.8% +$8.3K 0.04% 429
2022
Q2 		$934K Buy
25,081
+878
+4% +$35.7K 0.04% 436
2022
Q1 		$1.07M Buy
24,203
+12,096
+100% +$524K 0.04% 411
2021
Q4 		$514K Sell
12,107
-11,631
-49% -$489K 0.03% 445
2021
Q3 		$1.03M Buy
23,738
+1,104
+5% +$48.8K 0.05% 363
2021
Q2 		$968K Sell
22,634
-1,160
-5% -$48.8K 0.05% 383
2021
Q1 		$920K Buy
23,794
+7,538
+46% +$285K 0.05% 365
2020
Q4 		$584K Buy
16,256
+426
+3% +$15.4K 0.04% 405
2020
Q3 		$605K Buy
15,830
+427
+3% +$16.5K 0.05% 350
2020
Q2 		$541K Buy
15,403
+1,471
+11% +$53K 0.05% 357
2020
Q1 		$455K Buy
13,932
+1,720
+14% +$67.2K 0.05% 355
2019
Q4 		$552K Buy
12,212
+776
+7% +$32.5K 0.05% 372
2019
Q3 		$465K Buy
11,436
+526
+5% +$22.3K 0.05% 356
2019
Q2 		$469K Sell
10,910
-3
-0% -$115 0.05% 337
2019
Q1 		$419K Buy
+10,913
New +$417K 0.05% 344

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Snowden Capital Advisors's BSX Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Boston Scientific (BSX) stake by 4.8% in Q2 2026, selling an estimated $37.5K and leaving 13,777 shares worth $588K. The position accounts for 0.01% of the portfolio, ranked #775.

Snowden Capital Advisors first reported a position in BSX in Q1 2019 and has held it in 30 quarters since. The position peaked at $2.35M in Q1 2025. 1,481 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Snowden Capital Advisors held 13,777 shares of Boston Scientific worth $588K as of Q2 2026.
  • Snowden Capital Advisors sold 690 Boston Scientific shares in Q2 2026, an estimated $37.5K.
  • Boston Scientific made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #775 holding.
  • Snowden Capital Advisors first reported a position in Boston Scientific in Q1 2019 and has held it in 30 quarters since.
  • Snowden Capital Advisors's Boston Scientific position peaked at $2.35M in Q1 2025.
  • 1,481 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.